Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

ClinicalTrials.gov ID: NCT03007407

Public ClinicalTrials.gov record NCT03007407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy

Study identification

NCT ID
NCT03007407
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NSABP Foundation Inc
Network
Enrollment
33 participants

Conditions and interventions

Interventions

  • durvalumab Drug
  • Tremelimumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 30, 2017
Primary completion
Apr 17, 2019
Completion
Aug 8, 2019
Last update posted
Dec 4, 2022

2017 – 2019

United States locations

U.S. sites
18
U.S. states
6
U.S. cities
14
Facility City State ZIP Site status
City of Hope Duarte California 91010
Smilow Cancer Hospital at Yale-New Haven New Haven Connecticut 06510
Smilow Cancer Hospital Care Center at North Haven North Haven Connecticut 06473
UF Health Davis Cancer Pavilion and Shands Med Plaza Gainesville Florida 32608
UF Health Shands Cancer Hospital Gainesville Florida 32608
UF Health Shands Hospital Gainesville Florida 32610
University of Florida Gainesville Florida 32610
University of Florida Health Cancer Center at Orlando Health Orlando Florida 32806
Centralia Oncology Clinic Centralia Illinois 62801
Cancer Care Specialists of Central Illinois Decatur Illinois 62526
Cancer Care Specialists of Central Illinois/Crossroads Cancer Center Effingham Illinois 62401
Cancer Care Specialists of Central Illinois-Swansea Swansea Illinois 62226
Trinity Health Michigan Ann Arbor Michigan 48106
University of Michigan Ann Arbor Michigan 48109
St. Joseph Mercy-Brighton Brighton Michigan 48114
St. Joseph Mercy-Canton Canton Michigan 48188
St Joseph Mercy-Chelsea Chelsea Michigan 48118
Thomas Jefferson University Philadelphia Pennsylvania 19107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03007407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 4, 2022 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03007407 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →